OpenASO: RNA Rescue — designing splice-modulating antisense oligonucleotides through community science
- Victor Tse1,
- Martin Guiterrez1,
- Jill Townley2,
- Jonathan Romano2,
- Jennifer Pearl2,
- Guillermo Chacaltana1,
- Eterna Players2,
- Rhiju Das3,
- Jeremy Sanford1 and
- Michael Stone4,5
- 1 University of California Santa Cruz ;
- 2 Eterna Massive Open Laboratory ;
- 3 Stanford University ;
- 4 University of California
- ↵* Corresponding author; email: mds{at}ucsc.edu
Abstract
Splice-modulating antisense oligonucleotides (ASOs) are precision RNA-based drugs that are becoming an established modality to treat human disease. Previously, we reported the discovery of ASOs that target a novel, putative intronic RNA structure to rescue splicing of multiple pathogenic variants of F8 exon 16 that cause hemophilia A. However, the conventional approach to discovering splice-modulating ASOs is both laborious and expensive. Here, we describe a novel approach that integrates data-driven RNA structure prediction and community science to discover splice-modulating ASOs. Using a splicing-deficient pathogenic variant of F8 exon 16 as a model, we show that 25% of the top-scoring molecules designed in the Eterna OpenASO challenge have a statistically significant impact on enhancing exon 16 splicing. Additionally, we show that a distinct combination of ASOs designed by Eterna players can additively enhance the inclusion of the splicing-deficient exon 16 variant. Together, our data suggests that crowdsourcing designs from a community of citizen scientists may accelerate and complement traditional avenues for the discovery of splice-modulating ASOs with potential to treat human disease.
Keywords
- Received October 15, 2024.
- Accepted May 6, 2025.
- Published by Cold Spring Harbor Laboratory Press for the RNA Society
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.










